For older people and frail people, the long-term benefit of medicines reduces and the potential for harm from adverse effects increases. When the benefit–risk balance changes in this way, medicine review and optimisation are important to simplify the therapeutic regimen, reduce inappropriate medicines and minimise risks. In this article, pharmacist prescriber Linda Bryant uses two case studies to illustrate important considerations during medicine reviews
Time to think winter…and chronic obstructive pulmonary disease
Time to think winter…and chronic obstructive pulmonary disease

The weather is getting cooler, so pharmacist prescriber Linda Bryant says it’s time to start planning for the onslaught of winter ailments, particularly chronic obstructive pulmonary disease
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
1. Hancox RJ, Jones S, Baggott C, et al. New Zealand COPD guidelines: Quick reference guide. N Z Med J 2021;134(1530):76–110.
2. Yang IA, George J, McDonald CF, et al. The COPD-X Plan: Australian and New Zealand Guidelines for the management of Chronic Obstructive Pulmonary Disease 2022. Version 2.68, October 2022.
3. Cole JM, Sheehan AH, Jordan JK. Concomitant use of ipratropium and tiotropium in chronic obstructive pulmonary disease. Ann Pharmacother 2012;46(12):1717–21.
4. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease: 2023 Report.